Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance

Core Insights - Lantheus Holdings, Inc. reported significant growth in its financial results for 2024, with a notable increase in worldwide revenue and the achievement of blockbuster status for its radiodiagnostic product PYLARIFY [2][4][5] - The company plans to expand its commercial portfolio and pipeline in 2025, focusing on innovative radiopharmaceutical solutions to enhance patient outcomes and shareholder value [2][6] Financial Performance - Worldwide revenue for Q4 2024 was $391.1 million, a 10.5$354.0 million in Q4 2023 [4][5] - Full-year revenue for 2024 reached $1.53 billion, up 18.3$1.30 billion in 2023 [4][20] - PYLARIFY sales were $266.0 million in Q4 2024, reflecting a 15.7$86.2 million [5][20] - The company reported a GAAP net loss of $11.8 million for Q4 2024, compared to a net income of$103.4 million in Q4 2023 [4][5] - Adjusted net income for Q4 2024 was $115.4 million, down 5.9$122.7 million in Q4 2023 [4][21] Strategic Initiatives - Lantheus has closed multiple strategic transactions in 2024, adding five new assets to its pipeline, including acquisitions that enhance its presence in prostate cancer and Alzheimer's disease diagnostics [6][7] - The company is focusing on diversifying its portfolio with early- to late-stage assets and expanding its capabilities in high-potential markets [2][6] - In 2025, Lantheus plans to acquire Life Molecular Imaging and Evergreen Theragnostics, which will strengthen its position in the radiopharmaceutical market [7][9] Guidance and Future Outlook - For FY 2025, Lantheus projects revenue between $1.545 billion and$1.610 billion, with adjusted fully diluted EPS guidance of $7.00 to$7.20 [9][10] - The company aims to continue executing a strategy that emphasizes sustainable growth and value creation for shareholders [2][6]